Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592508 | 0.74 | PDK1 (0.38) | TYRPDK1PDK2PDK3PDK4 | |
| SCHEMBL14478303 | 0.67 | HTR1A (0.51) | HSD17B10ESR1ALOX15ALOX12 | |
| SCHEMBL1607208 | 0.67 | HSD17B10 (0.52) | TYRHSD17B10ESR1ALOX15 | |
| SCHEMBL7289508 | 0.67 | ESRRB (0.40) | TYRPDK1PDK2PDK3PDK4 | |
| SCHEMBL4208352 | 0.66 | TYR (0.58) | TYRHSD17B10ESR1 | |
| SCHEMBL6166403 | 0.66 | HSD17B10 (0.56) | TYRHSD17B10ESR1IDO1ALOX15 | |
| SCHEMBL12305663 | 0.66 | HSD17B10 (0.46) | TYRPOLBHSD17B10ESR1OPRK1 | |
| SCHEMBL18887690 | 0.66 | ERCC1 (0.50) | POLB | |
| SCHEMBL9135588 | 0.65 | LMNA (0.57) | OPRK1ADRB2 | |
| SCHEMBL13995716 | 0.65 | OPRK1 (0.49) | TYRPOLBHSD17B10ESR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3424534-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-2651891-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651932-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2013092674-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2013064450-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2012080456-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080457-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109697-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | TYR 679/4885PDK1 2472/4885PDK2 1315/4885 |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | TYR 4272/4885PDK1 2749/4885PDK2 4438/4885 |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, SULT2A1 | TYR 402/4885PDK1 1701/4885PDK2 1454/4885 |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | TYR 732/4885PDK1 2556/4885PDK2 1354/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TYR 4596/4885PDK1 3838/4885PDK2 4646/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | TYR 4272/4885PDK1 2749/4885PDK2 4438/4885 |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | TYR 463/4885PDK1 1576/4885PDK2 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.